Direct-to-consumer misleading information on cancer risks calls for an urgent clarification of health genetic testing performed by commercial companies.
Eur J Cancer
; 132: 100-103, 2020 06.
Article
en En
| MEDLINE
| ID: mdl-32335476
ABSTRACT
Direct-to-consumer (DTC) commercial companies offer genetic tests that are presented as allowing individuals the opportunity to increase their capacities to be in charge of their own healthcare managements. DTC companies deny performing medical tests, yet they provide data based on sequencing multigene panel or whole exome. This contradiction allows these companies to escape the requirements of a regulated medical practice that guarantees the quality of the tests, as well as the information and support for tested individuals. Herein, we illustrate the lack of such requirements by analysing the bad experience of a young man who dealt with DTC health genetic testing companies. There is an emergency for DTC testing to be either deprived of any medically relevant information, or carried out in a legally regulated medical framework.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Pruebas Genéticas
/
Análisis de Secuencia de ADN
/
Difusión de la Información
/
Errores Diagnósticos
/
Industria Farmacéutica
/
Pruebas Dirigidas al Consumidor
/
Neoplasias
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Humans
/
Male
Idioma:
En
Revista:
Eur J Cancer
Año:
2020
Tipo del documento:
Article
País de afiliación:
Francia